JAGX Jaguar Health Inc.

0.44
-0.2  -31%
Previous Close 0.64
Open 0.43
Price To Book 1.91
Market Cap 9,306,776
Shares 21,199,945
Volume 12,473,734
Short Ratio
Av. Daily Volume 709,983
Stock charts supplied by TradingView

NewsSee all news

  1. Jaguar Health Announces Exercise of Warrants for $4.45 Million Gross Proceeds

    SAN FRANCISCO, CA / ACCESSWIRE / May 22, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has entered into agreements with several institutional and

  2. Jaguar Health Pursuing Contracting Opportunities with Insurers to Improve Patient Access for Company's Non-opioid Plant-Based Mytesi Drug Product

    A component of Napo's new market access program intended to help remove access barriers for people living with HIV to start and stay on Mytesi®SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2020 / Jaguar Health, Inc.

  3. Jaguar Health Reports Voting Results from May 15, 2020 Annual Meeting of Stockholders

    All Proposals ApprovedSAN FRANCISCO, CA / ACCESSWIRE / May 15, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results from the Annual

  4. Jaguar Health, Inc. Reports 2020 First Quarter Financial Results

    Reminder: Company to host investor call today at 8:30 a.m. EasternSAN FRANCISCO, CA / ACCESSWIRE / May 15, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported

  5. Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter Accounts Receivable Purchase Agreement with Oasis Capital, LLC

    April 2020 sales of Mytesi® generate gross accounts receivable of $2,753,639SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to enrol through to completion - November 14, 2019.
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
Protocol development for discussions with FDA.
Mytesi (crofelemer)
Inflammatory bowel disease (IBD)

Latest News

  1. Jaguar Health Announces Exercise of Warrants for $4.45 Million Gross Proceeds

    SAN FRANCISCO, CA / ACCESSWIRE / May 22, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has entered into agreements with several institutional and

  2. Jaguar Health Pursuing Contracting Opportunities with Insurers to Improve Patient Access for Company's Non-opioid Plant-Based Mytesi Drug Product

    A component of Napo's new market access program intended to help remove access barriers for people living with HIV to start and stay on Mytesi®SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2020 / Jaguar Health, Inc.

  3. Jaguar Health Reports Voting Results from May 15, 2020 Annual Meeting of Stockholders

    All Proposals ApprovedSAN FRANCISCO, CA / ACCESSWIRE / May 15, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results from the Annual

  4. Jaguar Health, Inc. Reports 2020 First Quarter Financial Results

    Reminder: Company to host investor call today at 8:30 a.m. EasternSAN FRANCISCO, CA / ACCESSWIRE / May 15, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported

  5. Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter Accounts Receivable Purchase Agreement with Oasis Capital, LLC

    April 2020 sales of Mytesi® generate gross accounts receivable of $2,753,639SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned

  6. Jaguar Health to Host Investor Call May 15th at 8:30 a.m. Eastern Regarding Q1 2020 Financials & Business Updates

    Company Plans to File Q1 2020 10-Q on May 14, 2020SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management

  7. Jaguar Health Clears Important Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Exercise-Induced Diarrhea (EID) in Dogs

    Canalevia is the first and only oral plant-based prescription drug candidate for EID in dogs Diarrhea is a common problem among working dogs subjected to intense, long-duration off-leash exerciseSAN FRANCISCO, CA /

  8. Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate

    Jaguar concurrently receives $1.5 million and exclusive 10-year license from purchaser to develop and commercialize NP-500 through sale of NP-500 technology and IPDeal brings in immediate non-dilutive capital to fund

  9. Jaguar Health, Inc. Initial Offering (FormS) (Amended) (0001104659-20-043807)

  10. Jaguar Health Reports 2019 Financial Results and Business Updates

    Mytesi® net sales and gross sales grew 38% and 44%, respectively, in 2019 compared to 2018Reminder: Company to host investor call Monday, April 6 at 8:30 a.m. EasternSAN FRANCISCO, CA / ACCESSWIRE / April 6, 2020 /

  11. Jaguar Health to Host Investor Call April 6th at 8:30 a.m. Eastern Regarding Q4 2019 Financials & Business Updates

    Company Filed its Annual Report on April 3, 2020 on Form 10-K for the Fiscal Year Ended December 31, 2019SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the

  12. Napo Pharmaceuticals Expands Mytesi (Crofelemer) Patient Support Program

    NapoCares™ patient support program provides FDA-approved, plant-based non-opioid Mytesi® to treat non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapyLaunch of expanded NapoCares program

  13. Jaguar Health Clears Key Regulatory Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs

    Canalevia would be first and only FDA-approved plant-based medicine for 50,000-plus dogs that suffer from diarrhea annually while undergoing chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2020 / Jaguar Health,

  14. Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Alleen King-Carter March 13, 2020 at 3 p.m. Eastern

    SAN FRANCISCO, CA / ACCESSWIRE / March 12, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals,

  15. Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream

    Transaction Proceeds Will be Allocated to Support Advancement of Regulatory Activities Associated with Jaguar's Pipeline, Including the Company's Lead Product Candidate, Crofelemer, for Cancer Therapy-related

  16. Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award

    SAN FRANCISCO, CA / ACCESSWIRE / February 20, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the nonprofit American Botanical Council (ABC) has given the

  17. Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Davina Otalor February 7, 2020 at 3 p.m. Eastern

    SAN FRANCISCO, CA / ACCESSWIRE / February 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals,

  18. Jaguar Health Announces that Published Study Indicates Crofelemer Could be a Treatment Option for Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome

    SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that a study appearing in the December 2019 issue of Clinical and

  19. Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV Patients

    SAN FRANCISCO, CA / ACCESSWIRE / December 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that a clinical research study initiated and sponsored by The

  20. Jaguar Health Subsidiary Napo Pharmaceuticals to Host HIV Activism Digital Summit December 13, 2019 at 3 p.m. Eastern

    SAN FRANCISCO, CA / ACCESSWIRE / December 10, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo

  21. Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern

    SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo

  22. Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine

    SAN FRANCISCO, CA / ACCESSWIRE / November 20, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that an article about the Company appears in the Fall 2019 issue of

  23. Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results

    Reminder: Company to Host Investor Call Today at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business

  24. Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients

    SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Georgetown University's Data Safety Monitoring Committee

  25. Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy

    Reminder: Company to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business

  26. Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates

    Company Plans to File Q3 2019 10-Q on November 14, 2019SAN FRANCISCO, CA / ACCESSWIRE / November 12, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company

  27. Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc.

    SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals,

  28. MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16th, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap

  29. Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China

    Jaguar Health Receives $1.75 Million in Proceeds from Warrant Exercise at an Exercise Price of $1.40SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the

  30. Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer

    SAN FRANCISCO, CA / ACCESSWIRE / October 4, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that a License Termination and Settlement agreement ("LTSA")

  31. Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs

    Reminder: Company to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi® (Crofelemer) for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea in

  32. Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application

    SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused

  33. Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern

    SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused

  34. Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea

    SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Thursday,

  35. Jaguar Health Comments on FDA's Decision to Set Packaging Limits for Anti-Diarrhea Medicine Loperamide (Imodium) to Encourage Safe Use

    Mytesi® Novel Anti-Diarrheal Mechanism of Action Distinguished as Non-OpioidSAN FRANCISCO, CA / ACCESSWIRE / September 23, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company")

  36. Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York

    SAN FRANCISCO, CA / ACCESSWIRE / September 19, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Lisa Conte, Jaguar's founder, president and CEO, will

  37. Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer

    Company's Legacy Animal Health Business Supports Focus on Human Health BenefitsSAN FRANCISCO, CA / ACCESSWIRE / September 18, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the

  38. Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico

    Puerto Rico Had the 7th Highest Cumulative Rate of HIV Infection in the Nation in 2016SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company")

  39. Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel

    SAN FRANCISCO, CA / ACCESSWIRE / September 9, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has promoted Jonathan Wolin, an accomplished healthcare and biotech

  40. Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs

    Company's Legacy Animal Health Business Supports Focus on Human Health BenefitsSAN FRANCISCO, CA / ACCESSWIRE / August 26, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the

  41. Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern

    SAN FRANCISCO, CA / ACCESSWIRE / August 22, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals,